Pfizer Canada, a unit of New York-based Pfizer Inc., advised Health Canada that there is a shortage of Epipen auto-injectors in the 0.3-mg format, reported due to a manufacturing disruption currently anticipated to be resolved by March 2. According to Pfizer, the shortage does not impact Epipen Jr (0.15 mg) products, which remain available.